Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.
Chung
Kuei-Pin
KP
National Taiwan University Hospital, Taipei, Taiwan.
Shih
Jin-Yuan
JY
Yu
Chong-Jen
CJ
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001483:Base Sequence; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002764:Cholecystitis / Q000150:complications / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004252:DNA Mutational Analysis; D005260:Female; D000077156:Gefitinib; D018773:Genes, erbB-1; D020022:Genetic Predisposition to Disease; D006801:Humans; D033162:Incidental Findings; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009154:Mutation; D009367:Neoplasm Staging; D010375:Pedigree; D011013:Pneumonectomy; D011799:Quinazolines / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
D000970:Antineoplastic Agents; D011799:Quinazolines; D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine; D000077156:Gefitinib